JUN 1 0 2004

510(k) SUMMARY

Submitter Information: TOTOKU ELECTRIC CO., LTD.

300 Oya, Ueda

Nagano 386-0192 Japan

Contact Person:

Mikio Hasegawa, General Manager

Email: haseqawam@totoku.co.jp

Tel:+81.268.34.5469 Fax:+81.268.34.5548

Date Prepared: March 15, 2004

Device Name: 21.3-inch (54cm) Color LCD Monitor CCL212 (CDL2107A)

Common Name: CCL212, CDL2107A, 2M Monitor/Display

Classification Name: Class II

(Part 892 Radiology Devices

Sec. 892,2050 Picture Archiving and Communication System)

Predicate Device: CDL2005A (K021738)

Device Description:

Best suited for CT and MRI, CCL212 (CDL2107A) is a 21.3-inch high definition color medical imaging LCD monitor with higher luminance (450cd/m²) and longer lifetime (three times as long as our existing models). With λ -Sentinel, a luminance stabilizing circuit, mounted, CCL212 (CDL2107A) delivers stable display of

images.

Indended Use:

21.3-inch (54cm) Color LCD Monitor CCL212 (CDL2107A) is to be used in conjunction with the picture archiving communication systems (PACS) for medical imaging applications. It is not meant

to be used for digital mammography.

Substantial Equivalence:

CCL212 (CDL2107A) shares the same characteristics with our predicate device CDL2005A (K021738) except for the panel which is superior to the predicate device in display area, luminance, and number of photo sensors and serial communication connectors

available. It also has a three-times longer lifetime.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUN 1 0 2004

Mr. Mikio Hasegawa General Manager Totoku Electric Co., Ltd. MM Company, design Group 300 Oya, Ueda Nagano 386-0192 JAPAN Re: K040697

Trade/Device Name: 21.3-inch (54cm) Color LCD

Monitor CCL212 (CDL2107A)

Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving

and communications system

Regulatory Class: II Product Code: 90 LLZ Dated: March 15, 2004 Received: March 17, 2004

Dear Mr. Hasegawa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Mancy C. Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

K\$49697

510(k) Number: Not Known

Device Name: 21.3-inch (54cm) Color	r LCD Monitor C	CL212 (CDL2107A)
Indications for Use:		
21.3-inch (54cm) Color LCD Monito	or CCL212 (CDL	2107A) is to be used in conjunction with
the picture archiving communicat	ion systems (PA	CS) for medical imaging applications. It
is not meant to be used for digital	mammography	•
./		
Prescription Use	ÆNÐ /OR	Over-The-Counter Use
(Part 21 CFR 801 Subpart D)		(21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW T	THIS LINE-CONTI	NUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CD	ORH, Office of De	vice Evaluation (ODE)

(Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices KO40697